Objective To assess the reporting, extent, and handling of loss to follow-up and its potential
impact on the estimates of the effect of treatment in randomised controlled trials. Design …

A number of pharmacologic treatments examined in recent randomized clinical trials (RCTs)
have failed to show statistically significant superiority to placebo in conditions in which their …

High quality protocols facilitate proper conduct, reporting, and external review of clinical
trials. However, the completeness of trial protocols is often inadequate. To help improve the …

Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin
in patients with venous thromboembolism is unclear. Methods In a randomized, double …

Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-
glucose co-transporter-2 (SGLT2) inhibitors improve glycaemic control and reduce …

Missing data affect nearly every discipline by complicating the statistical analysis of collected
data. But since the 1990s, there have been important developments in the statistical …

The use of multiple imputation has increased markedly in recent years, and journal
reviewers may expect to see multiple imputation used to handle missing data. However in …

The current novel coronavirus disease 2019 (COVID-19) pandemic has led to substantial
changes in health risks, access to health care, and daily interactions. Through these and …

Background and Purpose—The guidelines presented in this consensus statement are
intended to serve researchers, clinicians, reviewers, and regulators in the selection of the …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …